Gene Editing Market

Report Overview

The Gene Editing Market Size is expected to be worth around US$ 36.9 billion by 2033 from US$ 7.8 billion in 2023, growing at a CAGR of 16.8% during the forecast period 2024 to 2033.

Increasing advancements in gene editing technologies significantly drive growth in the market, particularly as applications expand across healthcare, agriculture, and biotechnology. The ability to precisely modify genes opens new avenues for treating genetic disorders, enhancing crop resilience, and improving industrial biotechnology processes. In September 2021, the UK’s Department for Environment, Food and Rural Affairs (Defra) announced that researchers would no longer need to submit risk assessments for field trials of gene-edited plants by the end of 2021, streamlining the development of genetically modified crops.

Recent collaborations further underscore this trend; in July 2023, Sangamo Therapeutics partnered with Chroma Medicine to explore the potential of epigenetic medicines, utilizing Sangamo’s Zinc Finger Proteins (ZFPs) for specific targets beyond the central nervous system, with plans for future licensing and commercialization. Additionally, LGC’s acquisition of Rapid Genomics in April 2022 strengthened its position in next-generation sequencing (NGS) applications, enhancing capabilities in high-throughput genotyping within the agrigenomics market.

These developments reflect a broader trend toward integrating gene editing with other technologies, fostering innovation in personalized medicine and sustainable agriculture. The rising focus on ethical considerations and regulatory frameworks also presents opportunities for market growth, as stakeholders strive to balance technological advancements with public safety. As researchers and companies continue to innovate, the gene editing market is poised for significant expansion, driven by a commitment to solving pressing global challenges in health and food security.

Key Takeaways

• In 2023, the market for gene editing generated a revenue of US$ 16.8 billion, with a CAGR of 16.8%, and is expected to reach US$ 36.9 billion by the year 2033.
• The product type segment is divided into reagents & consumables, software & systems, and services, with reagents & consumables taking the lead in 2023 with a market share of 58.6%.
• Considering technology, the market is divided into CRISPR, zinc finger nuclease, transcription activator-like effector nuclease, antisense, and others. Among these, CRISPR held a significant share of 53.5%.
• Furthermore, concerning the application segment, the market is segregated into cell line engineering, drug discovery & development, genetic engineering, and others. The cell line engineering sector stands out as the dominant player, holding the largest revenue share of 49.8% in the gene editing market.
• The end-user segment is segregated into pharmaceutical & biotechnology companies and academic & research institutes, with the pharmaceutical & biotechnology companies segment leading the market, holding a revenue share of 52.1%.
• North America led the market by securing a market share of 41.2% in 2023.

Product Type Analysis

The reagents & consumables segment led in 2023, claiming a market share of 58.6% owing to the increasing demand for high-quality tools essential for precise editing processes. As researchers and biotechnology companies expand their efforts in genetic manipulation, the need for reliable reagents and consumables is anticipated to rise. Innovations in reagents, such as optimized enzymes and delivery systems, are likely to enhance the efficiency and accuracy of gene editing techniques.

Additionally, the ongoing development of protocols and standardization of workflows will further stimulate the demand for consumables. The growing emphasis on personalized medicine and therapeutic applications will contribute to this segment’s expansion, as high-quality reagents are vital for successful outcomes in clinical settings. Consequently, as the gene editing landscape evolves, the reagents and consumables segment is poised to play a crucial role in supporting advancements in this field.

Technology Analysis

The CRISPR held a significant share of 53.5% due to its revolutionary impact on genetic engineering. The increasing adoption of CRISPR technology in research and therapeutic applications is expected to drive demand, given its unparalleled precision and efficiency compared to traditional methods. Researchers are likely to favor CRISPR due to its cost-effectiveness and versatility, which make it applicable in various fields, including agriculture, medicine, and biotechnology.

The ongoing advancements in CRISPR-based tools, such as CRISPR-Cas9 and CRISPR-Cas12, are anticipated to enhance its capabilities, allowing for more sophisticated editing tasks. Furthermore, the growing interest in gene therapies and genomic medicine is expected to foster innovation within the CRISPR segment, reinforcing its position as a leading technology in gene editing. Overall, the CRISPR segment is likely to continue driving significant growth in the gene editing market.

Application Analysis

The cell line engineering segment had a tremendous growth rate, with a revenue share of 49.8% owing to the rising demand for engineered cell lines in drug discovery and development. The ability to create cell lines with specific genetic modifications is crucial for researchers looking to understand disease mechanisms and develop targeted therapies.

The increasing focus on biopharmaceuticals and the need for efficient screening processes are anticipated to drive the adoption of cell line engineering techniques. Furthermore, advancements in gene editing technologies, such as CRISPR, will likely enhance the precision and efficiency of creating these cell lines, making them more attractive for research and development purposes.

The growing emphasis on personalized medicine will also contribute to this segment’s expansion, as engineered cell lines can provide more relevant models for testing therapeutics tailored to individual patient profiles. As a result, the cell line engineering segment is projected to play a vital role in the ongoing advancement of the gene editing market.

End-user Analysis

The pharmaceutical & biotechnology companies segment grew at a substantial rate, generating a revenue portion of 62.1% due to their increasing investment in research and development activities. As these companies seek to develop innovative therapies and improve drug discovery processes, the demand for advanced gene editing technologies is expected to rise significantly. The growing focus on targeted therapies and personalized medicine will likely encourage pharmaceutical and biotechnology firms to adopt gene editing techniques to enhance treatment efficacy.

Additionally, collaborations between these companies and academic institutions are anticipated to foster innovation and accelerate the translation of research into practical applications. The expanding pipeline of gene therapies and the rising number of clinical trials utilizing gene editing technologies will further solidify the importance of this segment. As the market evolves, pharmaceutical and biotechnology companies are expected to remain at the forefront of advancements in gene editing, driving substantial growth in this sector.

Key Market Segments

By Product Type

• Reagents & Consumables
• Software & Systems
• Services

By Technology

• CRISPR
• Zinc Finger Nuclease
• Transcription Activator-like Effector Nuclease
• Antisense
• Others

By Application

• Cell Line Engineering
• Drug Discovery & Development
• Genetic Engineering
• Others

By End-user

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes

Drivers

Increasing Research and Development

Increasing research and development efforts significantly drive the gene editing market. The ongoing exploration of genomic medicine has led to innovative breakthroughs in therapeutic applications. In October 2023, Integrated DNA Technologies (IDT), a subsidiary of Danaher Corporation, inaugurated a new therapeutic manufacturing facility designed to address the growing demand for genomic medicine.

This facility enhances production capabilities for therapeutic oligonucleotides, which are essential for advancing gene therapies and personalized medicine. Furthermore, in May 2023, researchers at the Lewis Katz School of Medicine at the University of Nebraska Medical Center reported successful treatment of HIV infection in animals using CRISPR technology.

Such advancements highlight the potential of gene editing to transform medical treatments. As investment in R&D continues to rise, the market is expected to experience robust growth, providing significant opportunities for innovation and application in various therapeutic areas.

Restraints

Off-Target Impact of CRISPR Technology Restraints Market Expansion

High levels of concern regarding the off-target impact of CRISPR technology restrain the growth of the gene editing market. While CRISPR has revolutionized genetic modification with its precision, unintended edits at non-targeted sites can raise safety concerns. These off-target effects may impede researchers’ confidence in using gene editing technologies for therapeutic purposes, especially in clinical applications where safety is paramount.

Additionally, regulatory bodies may impose stringent guidelines on the use of CRISPR, further complicating its acceptance in medical research and treatment. As long as these concerns persist, they are expected to hamper the market’s expansion by limiting the scope of applications and increasing the scrutiny of gene editing technologies. Addressing these challenges through improved precision and safety measures will be essential for fostering greater acceptance and driving market growth.

Opportunities

Advancements in Gene Editing Services Create Opportunities

Rising advancements in gene editing services present significant opportunities for the market. The continuous development of improved technologies and methodologies enhances the efficacy and accessibility of gene editing applications. For instance, in April 2021, GenScript launched a Research-Grade Lentiviral Vector Packaging Service, aimed at supporting drug discovery, cell line development, and gene editing projects. This service provides researchers with essential tools for advancing their work in genomics.

As more companies invest in innovative gene editing solutions and expand their service offerings, the market is expected to see increased demand from academic and commercial sectors alike. Furthermore, the growing interest in personalized medicine and targeted therapies will likely drive the need for advanced gene editing services, positioning the market for substantial growth and innovation in the coming years.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic and geopolitical factors significantly influence the market for genetic modification technologies. Economic fluctuations can lead to reduced funding for research and development, restricting innovation and slowing the progress of new treatments. Rising costs of raw materials and labor can increase the overall expenses associated with developing and commercializing gene editing solutions.

Geopolitical tensions may disrupt supply chains, affecting the availability of essential components for research. However, the growing prevalence of genetic disorders and the rising demand for precision medicine create substantial opportunities for market expansion. Additionally, increased public interest in gene therapies fosters investment from both private and public sectors.

Overall, while challenges arise from economic and geopolitical uncertainties, the ongoing commitment to advancing genetic technologies presents a positive outlook for the industry.

Trends

Impact of Collaborations on the Gene Editing Market

Growing collaboration among key players is expected to drive significant growth in the market for genetic modification technologies. Companies increasingly form partnerships to leverage complementary strengths and accelerate the development of innovative therapies. This trend enhances resource sharing, leading to faster advancements in genetic research and application. For instance, in November 2023, Cellectis and AstraZeneca entered into a collaboration agreement aimed at accelerating the development of advanced therapeutics in oncology and immunology.

Additionally, in January 2024, Danaher Corporation partnered with the Innovative Genomics Institute (IGI) to develop CRISPR-based therapies for rare genetic disorders, utilizing Danaher’s technological resources alongside IGI’s academic expertise. As the market experiences a surge in such strategic alliances, industry players are likely to enhance their capabilities and accelerate the introduction of groundbreaking gene editing solutions, ultimately benefiting patients and healthcare systems.

Regional Analysis

North America is leading the Gene Editing Market

North America dominated the market with the highest revenue share of 41.2% owing to advancements in biotechnology and increasing applications across various therapeutic areas. The rising prevalence of genetic disorders, alongside a growing focus on personalized medicine, has heightened the demand for innovative solutions that can effectively modify genes to treat or prevent diseases.

Notably, in June 2023, CRISPR Therapeutics and Vertex Pharmaceuticals submitted Biologics License Applications to the U.S. FDA for an ex-vivo CRISPR-based gene editing therapy aimed at treating sickle cell disease. This pivotal step demonstrates the progress being made in developing gene therapies that offer hope for patients with previously difficult-to-treat conditions.

Moreover, substantial investments in research and development from both public and private sectors have spurred innovation, leading to the discovery of new applications for gene editing technologies. The increasing collaboration between academic institutions and biotech companies has also contributed to a thriving ecosystem, further enhancing market growth. Overall, these factors have established a dynamic and robust environment for the gene editing market in North America.

The Asia Pacific region is expected to experience the highest CAGR during the forecast period

In the Asia Pacific region, the gene editing market is expected to see substantial growth during the forecast period. The rising incidence of genetic disorders and an increasing focus on innovative therapeutic approaches are anticipated to drive demand for gene editing technologies. Countries such as China, Japan, and India are likely to make significant investments in biotechnology research and development, fostering an environment conducive to growth.

The ongoing advancements in gene editing techniques, including CRISPR and TALEN, are projected to enhance the efficiency and accuracy of genetic modifications. Additionally, the growing interest in agricultural applications of gene editing, such as developing disease-resistant crops, is likely to further stimulate market expansion.

Furthermore, increasing awareness about the potential of gene therapies to address unmet medical needs will promote acceptance and adoption of these technologies. As healthcare systems in the region evolve and adapt to the demands for advanced treatment options, the gene editing market in Asia Pacific is expected to flourish, driven by innovation and investment in biotechnology.

Key Regions and Countries

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia
  • Netherland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • New Zealand
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

Key Players Analysis

The major players in the gene editing market are actively engaged in the development and introduction of innovative products, as well as implementing strategic initiatives aimed at enhancing their competitive positioning. Key players in the gene editing market focus on innovation and collaboration to drive growth and expand their technological capabilities.

They invest heavily in research and development to enhance existing editing techniques, such as CRISPR-Cas9 and TALEN, while also exploring new methodologies that improve precision and efficiency. Forming strategic partnerships with academic institutions, biotechnology firms, and pharmaceutical companies allows them to leverage expertise and share resources for advanced research initiatives.

Companies actively pursue regulatory compliance and establish clear intellectual property strategies to protect their innovations and foster investor confidence. Additionally, they target emerging markets, adapting their solutions to meet local healthcare needs and expanding access to gene therapies globally.

Top Key Players in the Gene Editing Market

• Thermo Fisher-Scientific
• Synthego
• Precision BioSciences
• Ginkgo Bioworks
• Crown Bioscience, Inc.
• Creative Biogene
• Carolina Biological Supply Company
• Bean Therapeutics
• Agilent Technologies

Recent Developments

• In February 2024: Precision BioSciences granted Caribou Biosciences a non-exclusive, global license to utilize its patented technology for the targeted insertion of exogenous antigen binding receptors into the TRAC gene locus of human T cells. This agreement includes an upfront payment, royalties on product sales, and potential milestone payments. This strategic collaboration is expected to drive growth in the gene editing market by facilitating the development of innovative therapies that leverage advanced gene editing techniques.
• In February 2024: Ginkgo Bioworks announced its acquisition of Proof Diagnostics, thereby expanding its product portfolio in gene editing toolkits for therapeutics. This acquisition enhances Ginkgo’s capabilities and strengthens its position in the gene editing market, contributing to the advancement of therapeutic applications and innovations in genetic engineering.
• In March 2024: Carolina Biological Supply Company partnered with the ChristianaCare Gene Editing Institute to develop an exclusive “CRISPR in a Box” educational kit aimed at students in grades 9 to 12 and higher education. This kit offers hands-on exercises designed to teach CRISPR techniques, which is essential for fostering interest and understanding in gene editing among future scientists. By educating the next generation, this initiative supports the long-term growth of the gene editing market.
• In December 2022: Crown Bioscience, Inc., a contract research organization (CRO), collaborated with ERS Genomics Limited to gain access to ERS’ CRISPR/Cas9 patent portfolio, thereby strengthening its market presence in the gene editing field. Such collaborations are anticipated to enhance outsourcing opportunities in the genome editing domain, positively impacting market growth by promoting the development and application of CRISPR technologies.